Pharmacist documentation of fentanyl patch orders in an academic medical center

Hospital Pharmacy

Volumn 46, Issue 11, 2011, Pages 854-863

  Jahansouz, Farivar ^a   Hsiao, Judy ^a   Dhillon, Krishma ^a   Helmons, Pieter ^a   Lamott, Jo Anna ^a   Kolan, Shobha ^a   Atayee, Rabia ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

documentation; fentanyl; guideline adherence; hospital policy; long acting opioids; pharmacists; quality improvement; REMs; retrospective studies; transdermal patch

Indexed keywords

FENTANYL;

ADULT; AGED; ARTICLE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; OUTPATIENT CARE; OVERSEDATION; PATIENT SAFETY; PHARMACIST; QUALITY CONTROL; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; UNITED STATES; UNIVERSITY HOSPITAL;

EID: 80955140381     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4611-854     Document Type: Article

References (12)

1. Duragesic (fentanyl transdermal system) [package insert]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; July 2009.
2. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997;53(1):109-138. (Pubitemid 27042235)
3. Kress HG, Von der Laage D, Hoerauf KH, et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage. 2008;36(3):268-279.
4. Allison C. Safety and appropriate use of fentanyl transdermal patches. The Prescription [serial online]. 2009;5(1):1-3.
5. US Food and Drug Administration. FDA issues second safety warning on fentanyl skin patch deaths and serious injuries from improper use. FDA news release www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm 109046.htm. Accessed December 28, 2010.
6. Cohen MR, Smetzer JL. ISMP medication error report analysis: ongoing incidents involving fentanyl patches are alarming!; Insulin concentrate U-500; WHO: dilute vincristine in a minibag. Hosp Pharm. 2007;42(10):884-888. (Pubitemid 350032541)
7. Jumbelic MI. Deaths with transdermal fentanyl patches. Am J Forensic Med Pathol. 2010;31:18-21.
8. 42 California Federal Regulations, Part 482.25 Condition of Participation: Pharmaceutical Services (b) Standard: Delivery of Services.
9. Dolophine hydrochloride (methadone) [package insert]. Columbus, OH: Roxane Laboratories, Inc.; October 2006.
10. Exalgo (hydromorphone hydrochloride) [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc; 2010.
11. Butrans (buprenorphine transdermal system) [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010.
12. Gordon A, Rashiq S, Moulin D, et al. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag. 2010;15(3):169-178.